肿瘤微环境在骨癌痛中作用的新进展

基础医学与临床 ›› 2021, Vol. 41 ›› Issue (3): 448-451.

肿瘤微环境在骨癌痛中作用的新进展

周佳宏, 李民^*

北京大学第三医院麻醉科, 北京 100191

收稿日期:2020-08-07 修回日期:2020-12-07 出版日期:2021-03-05 发布日期:2021-03-01
通讯作者: ^*liminanesth@aliyun.com

Advances on the roles of tumor microenvironment in bone cancer pain

ZHOU Jia-hong, LI Min^*

Department of Anesthesiology, Peking University Third Hospital, Beijing 100191, China

Received:2020-08-07 Revised:2020-12-07 Online:2021-03-05 Published:2021-03-01
Contact: ^*liminanesth@aliyun.com

摘要/Abstract

摘要： 肿瘤微环境(TME)是肿瘤在人体中赖以生存的环境,骨性癌痛(CIBP)是肿瘤骨转移最常见的并发症。骨癌痛(BCP)的机制复杂,肿瘤酸性微环境、相关离子通道及肿瘤细胞在微环境中分泌的炎性介质在骨癌痛中起作用。

关键词: 肿瘤微环境, 骨癌痛, 炎性介质

Abstract: Tumor microenvironment (TME) is the in vitro microenvironment in which tumors live. Cancer-induced bone pain(CIBP) is one of the most common symptoms of tumor bone metastasis. The mechanisms of bone cancer pain(BCP) are complex, and the tumor acidic microenvironment, the related ion channels and inflammatory mediators released by cancer, play a role in BCP.

Key words: tumor microenvironment, bone cancer pain, inflammatory mediators

中图分类号:

R363

周佳宏, 李民. 肿瘤微环境在骨癌痛中作用的新进展[J]. 基础医学与临床, 2021, 41(3): 448-451.

ZHOU Jia-hong, LI Min. Advances on the roles of tumor microenvironment in bone cancer pain[J]. Basic & Clinical Medicine, 2021, 41(3): 448-451.

参考文献

[1] Zajączkowska R, Kocot-Kępska M, Leppert W, et al. Bone pain in cancer patients: mechanisms and current treatment[J]. Int J Mol Sci, 2019, 20: 6047-6066.
[2] Wang L, Huo M, Chen Y, et al. Tumor microenviron-ment-enabled nanotherapy[J]. Adv Healthc Mater, 2018, 7: e1701156-e1701178.
[3] 曹峰琦, 陈翀, 刘妍, 等. 肿瘤pH微环境通过激活β-catenin/TCF4增强人乳腺癌肿瘤细胞的干性[J]. 基础医学与临床, 2014, 034: 622-627.
[4] Li Z, Yu C, Chen Y, et al. A novel water-soluble fluorescent probe with ultra-sensitivity over a wider pH range and its application for differentiating cancer cells from normal cells[J]. Analyst, 2019, 144: 6975-6980.
[5] Zhu S, Zhu J, Zhen G, et al. Subchondral bone osteoclasts induce sensory innervation and osteoarthritis pain[J]. J Clin Invest, 2019, 129: 1076-1093.
[6] Li M, Zhu M, Xu Q, et al. Sensation of TRPV1 via 5-hydroxytryptamine signaling modulates pain hypersensitivity in a 6-hydroxydopamine induced mice model of Parkinson's disease[J]. Biochem Biophys Res Commun, 2020, 521: 868-873.
[7] Zhang S, Zhao J, Meng Q. AAV-mediated siRNA against TRPV1 reduces nociception in a rat model of bone cancer pain[J]. Neurol Res, 2019, 41: 972-979.
[8] Lee H, Ahn S, Ann J, et al. Discovery of dual-acting opioid ligand and TRPV1 antagonists as novel therapeutic agents for pain[J]. Eur J Med Chem, 2019, 182: 111634-111634.
[9] Yoneda T, Hiasa M, Nagata Y, et al. Contribution of acidic extracellular microenvironment of cancer-colonized bone to bone pain[J]. Biochim Biophys Acta, 2015, 1848: 2677-2684.
[10] Brusco I, Li Puma S, Chiepe KB, et al. Dacarbazine alone or associated with melanoma-bearing cancer pain model induces painful hypersensitivity by TRPA1 activa-tion in mice[J]. Int J Cancer, 2020, 146: 2797-2809.
[11] Denadai-Souza A, Martin L, de Paula MA, et al. Role of transient receptor potential vanilloid 4 in rat joint inflammation[J]. Arthritis Rheum, 2012, 64: 1848-1858.
[12] Heo MH, Kim JY, Hwang I, et al. Analgesic effect of quetiapine in a mouse model of cancer-induced bone pain[J]. Korean J Intern Med, 2017, 32: 1069-1074.
[13] Zhu H, Ding J, Wu J, et al. Resveratrol attenuates bone cancer pain through regulating the expression levels of ASIC3 and activating cell autophagy[J]. Acta Biochim Biophys Sin (Shanghai), 2017, 49: 1008-1014.
[14] Remeniuk B, King T, Sukhtankar D, et al. Disease modifying actions of interleukin-6 blockade in a rat model of bone cancer pain[J]. Pain, 2018, 159: 684-698.
[15] Zhou YQ, Liu Z, Liu ZH, et al. Interleukin-6: an emerging regulator of pathological pain[J]. J Neuroinflammation, 2016, 13: 141-149.
[16] Chen JJ, Dai L, Zhao LX, et al. Intrathecal curcumin attenuates pain hypersensitivity and decreases spinal neuroinflammation in rat model of monoarthritis[J]. Sci Rep, 2015, 5: 10278-10289.
[17] Leo M, Schulte M, Schmitt LI, et al. Intrathecal resiniferatoxin modulates TRPV1 in DRG neurons and reduces TNF-induced pain-related behavior[J]. Mediators Inflamm, 2017, 2017: 2786427-2786434.
[18] Mazaki A, Orita S, Inage K, et al. Tumor necrosis factor-α produced by osteoclasts might induce intractable pain in a rat spinal metastasis model of breast cancer[J]. Spine Surg Relat Res, 2019, 3: 261-266.
[19] Mao Y, Wang C, Tian X, et al. Endoplasmic reticulum stress contributes to nociception via neuroinflammation in a murine bone cancer pain model[J]. Anesthesiology, 2020, 132: 357-372.
[20] Chen J, Cong X, Zhan X, et al. Effects of parecoxib on pain threshold and inflammatory factors IL-1β, IL-6 and TNF-α in spinal cord of rats with bone cancer pain[J]. J Coll Physicians Surg Pak, 2019, 29: 528-531.
[21] Kobayashi K, Omori K, Murata T. Role of prostaglandins in tumor microenvironment[J]. Cancer Metastasis Rev, 2018, 37: 347-354.
[22] Ma W, St-Jacques B. Signalling transduction events involved in agonist-induced PGE2/EP4 receptor externalization in cultured rat dorsal root ganglion neurons[J]. Eur J Pain, 2018, 22: 845-861.
[23] Park SH, Eber MR, Widner DB, et al. Role of the bone microenvironment in the development of painful complications of skeletal metastases[J]. Cancers (Basel), 2018, 10: 141-154.
[24] Ni S, Ling Z, Wang X, et al. Sensory innervation in porous endplates by Netrin-1 from osteoclasts mediates PGE2-induced spinal hypersensitivity in mice[J]. Nat Commun, 2019, 10: 5643-5657.